Fox Chase Cancer Center News

Stereotactic radiosurgery (SRS) offered results comparable to surgery in controlling local brain metastases, Fox Chase Cancer Center researchers have found. Early local control of treated lesions was better with SRS compared to those treated surgically, although the relative benefit decreased with time.

PHILADELPHIA (November 6, 2018) — Researchers at Fox Chase Cancer Center have created a mouse model that will make it possible to advance understanding of cystathionine beta synthase (CBS) deficiency, also known as classical homocystinuria.

PHILADELPHIA (November 5, 2018) — According to a new study, individuals living in rural areas are at greater risk of developing laryngeal cancer compared to those living in urban areas, though overall survival did not differ significantly between the two groups. Socioeconomic variables, including insurance status, had a greater impact on outcomes than geography or race.

PHILADELPHIA (November 1, 2018) — Stephen M. Sykes PhD, assistant professor in the Blood Cell Development and Function Program at Fox Chase Cancer Center, will conduct studies to assess the therapeutic utility of targeting downstream transcriptional targets and upstream activators within the unfolded protein response (UPR).

PHILADELPHIA (November 1, 2018) – The new Cancer Epigenetics Program Johnathan Whetstine, PhD, will lead has basic, translational, and clinical research components, all dedicated to better understanding epigenetic regulation in cancer.

The goal of this grant is to train, test, and use a deep learning model for predicting kinase inhibitor selectivity. The project is entitled “D3SC: EAGER: Deep Learning to Design Selective Kinase Inhibitors.”

PHILADELPHIA (October 30, 2018)— Namrata (Neena) Vijayvergia, MD, assistant chief of Gastrointestinal Medical Oncology, and Alexander Deneka, MD, PhD, postdoctoral fellow, both at Fox Chase Cancer Center, were among seven scientists selected to present at the Young Investigator Symposium at the semiannual ECOG-ACRIN Cancer Research Group meeting on October 25 in Fort Lauderdale, Florida.

PHILADELPHIA (October 29, 2018) – Vladimir Kolenko, MD, PhD, has received a grant from the Department of Defense to study histone-dependent PARP-1 inhibitors in the treatment of renal cell carcinoma. The objective of the proposal is to validate the therapeutic potential of novel PARP (poly ADP ribose polymerase)-1 inhibitors using clinically relevant cell and animal models of human clear cell renal cell carcinoma and investigate the mechanisms underlying their anti-tumor activity.